These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18315787)

  • 1. Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients.
    Ikawa K; Morikawa N; Ikeda K; Miki M; Nishimura S; Kobayashi M
    J Clin Pharm Ther; 2008 Apr; 33(2):203-10. PubMed ID: 18315787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients.
    Ikawa K; Morikawa N; Ikeda K; Miki M; Kobayashi M
    J Infect Chemother; 2010 Apr; 16(2):139-43. PubMed ID: 20094749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dosing regimen rationalization of biapenem in pediatric patients: use of Monte Carlo simulation].
    Kameda K; Miki M; Ikawa K; Morikawa N; Kobayashi M
    Jpn J Antibiot; 2009 Feb; 62(1):1-8. PubMed ID: 19378765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
    Int J Antimicrob Agents; 2008 Oct; 32(4):339-43. PubMed ID: 18602798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
    Ikawa K; Morikawa N; Ohge H; Ikeda K; Sueda T; Taniwaki M; Kurisu K
    J Infect Chemother; 2010 Feb; 16(1):25-32. PubMed ID: 20082106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients.
    Ikawa K; Kozumi T; Ikeda K; Morikawa N; Kobayashi R
    Jpn J Antibiot; 2009 Oct; 62(5):435-44. PubMed ID: 20055120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
    Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients.
    Ikawa K; Nomura K; Morikawa N; Ikeda K; Ohge H; Sueda T; Taniwaki M
    J Infect Chemother; 2008 Apr; 14(2):130-6. PubMed ID: 18622676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
    Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
    J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
    Lee DG; Choi SM; Shin WS; Lah HO; Yim DS
    Int J Antimicrob Agents; 2006 Oct; 28(4):333-9. PubMed ID: 16942864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T; Suyama H; Doi M; Kuwabara M
    Chemotherapy; 2008; 54(5):386-94. PubMed ID: 18769027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
    Du X; Li C; Kuti JL; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2006 Jan; 46(1):69-75. PubMed ID: 16397286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
    Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
    Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.
    Usman M; Frey OR; Hempel G
    Eur J Clin Pharmacol; 2017 Mar; 73(3):333-342. PubMed ID: 27966034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
    Chung EK; Fleming MR; Cheatham SC; Kays MB
    Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage.
    Kimura T; Kokubun H; Nowatari M; Matsuura N; Sunakawa K; Kubo H
    J Antimicrob Chemother; 2001 Jan; 47(1):51-9. PubMed ID: 11152431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.